

Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

Poster Session I ajog.org

Similarly, recipient demise had higher stages when compared to alive recipients (OR 0.51; 95% CI: 0.26, 1.00, P 0.05) (Figure 1).

When incidence of fetal demise was compared between stages II and I, no difference was observed for donor or recipient demise (Figure 2). When risk of fetal demise was compared between stages III and I, donor demise was more common in stage III (OR 2.67; 95% CI: 1.44, 4.98, P 0.002), but no difference was found for recipient demise (Figure 3). Pregnancies with donor demise had lower GA at the time of FLS (weeks) (mean difference -0.53; 95% CI: -0.96, -0.10, P 0.020), while pregnancies complicated by recipient demise had similar GA at time of FLP comapred to those without demise (Figure 4).

CONCLUSION: Earlier GA at FLP is associated with increased risk of single fetal demise in TTTS as compared to later GA. This difference was attributed to increased donor but not recipient death. Additionally, single demise of the donor and recipient was significantly observed after FLP for higher stages (III and IV) compared to lower ones (I and II). When rates of single fetal demise after FLP for stages II and III were individually compared to stage I, mortality was similar in stage II but not in stage III. The finding of stage III in TTTS increased risk of single fetal demise of the donor but not the recipient.

Fig 1. Fetal demise in low- and high-Quintero stage

	fetal demise Ali			ive Odds Ratio				Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	Year	M-H, Random, 95% CI
1.1.1 donor demise								
Kontopoulos 2007: donor	21	91	141	310	33.3%	0.36 [0.21, 0.61]	2007	-
Morris 2010: donor	4	81	12	281	7.1%	1.16 [0.37, 3.71]	2010	
Eixarch 2013: donor	9	33	91	182	14.3%	0.38 [0.17, 0.85]	2013	
Snowise 2015: donor	5	20	67	134	8.4%	0.33 [0.11, 0.97]	2015	-
Eschbach 2016: donor Subtotal (95% CI)	11	30 255	82	192 1099	15.1% 78.2%	0.78 [0.35, 1.72] 0.48 [0.31, 0.74]	2016	•
Total events	50		393					
Heterogeneity: Tau ² = 0.07:	Chi2 = 5.5	3. df = 4	(P = 0.24)	4): 2 = 2	28%			
Test for overall effect: $Z = 3.3$	30 (P = 0.0	010)						
1.1.2 recipient demise								
Morris 2010: recipient	0	24	16	304	1.2%	0.36 [0.02, 6.13]	2010	
Eixarch 2013- recipient	6	17	94	198	9.0%	0.60 [0.21, 1.70]	2013	
Eschbach 2016: recipient Subtotal (95% CI)	7	27 68	82	192 694	11.6%	0.47 [0.19, 1.16] 0.51 [0.26, 1.00]	2016	
Fotal events	13	00	192	034	21.070	0.51 [0.20, 1.00]		•
Heterogeneity: Tau* = 0.00:		0 44-3		13:12 - 0	nor.			
Test for overall effect: Z = 1.9			(F = 0.8	1), 1 – 1	170			
Total (95% CI)		323		1793	100.0%	0.47 [0.35, 0.65]		•
Total events	63		585					
Heterogeneity: Tau* = 0.00;	Chi ² = 5.8	0. df = 7	(P = 0.56)	6); J ² = (0%			0.01 0.1 1 10 10


Fig 2. Fetal demise in Quintero stage 1 vs stage 2

	fetal demise		Alive		Odds Ratio			Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	Year	M-H, Random, 95% CI
1.2.1 donor demise								
Kontopoulos 2007: donor	13	21	93	141	41.5%	0.84 [0.33, 2.16]	2007	_
Eixarch 2013; donor	8	9	68	91	8.2%	2.71 [0.32, 22.81]	2013	
Snowise 2015; donor	4	5	51	67	7.3%	1.25 [0.13, 12.05]	2015	
Eschbach 2016: donor Subtotal (95% CI)	8	11 46	63	82 381	18.4% 75.4%	0.80 [0.19, 3.34] 0.98 [0.49, 1.98]	2016	•
Total events	33		275					
Heterogeneity: Tau ² = 0.00;	Chi ² = 1.1	1. df = 3	(P = 0.7)	7); 2 =	0%			
Test for overall effect: $Z = 0$.	06 (P = 0.9	36)						
1.2.2 recipient demise								
Eixarch 2013- recipient	4	6	72	94	12.0%	0.61 [0.10, 3.56]	2013	
Eschbach 2016; recipient	5	7	63	82	12.6%	0.75 [0.14, 4.20]		
Subtotal (95% CI)		13		176	24.6%	0.68 [0.20, 2.33]		-
Total events	9		135					
Heterogeneity: Tau ² = 0.00:	Chi ² = 0.0	3. df = 1	(P = 0.8)	7): 2 =	1%			
Test for overall effect: Z = 0.				,,,				
Total (95% CI)		59		557	100.0%	0.90 [0.49, 1.65]		•
Total events	42		410					
Heterogeneity: Tau ² = 0.00:	Chi2 = 1.4	0. df = 5	(P = 0.9)	2): 2 =	0%			the state of the state of
Test for overall effect: Z = 0.								0.01 0.1 1 10 1
Test for subgroup difference			- 1 (P - I	0 61\ F	- 096			Favors stage Favors stage

Fig 3. Fetal demise in Quintero stage 1 vs stage 3

	fetal der	mise	Aliv	е		Odds Ratio		Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	Year	M-H, Random, 95% CI
1.3.1 donor demise								
Kontopoulos 2007: donor	66	74	130	178	45.4%	3.05 [1.36, 6.81]	2007	
Eixarch 2013: donor	22	23	83	106	7.0%	6.10 [0.78, 47.67]	2013	+
Snowise 2015: donor	14	15	59	75	6.7%	3.80 [0.46, 31.09]	2015	
Eschbach 2016: donor Subtotal (95% CI)	19	22 134	102	121 480	17.1% 76.1%		2016	•
Total events	121		374					
Heterogeneity: Tau ² = 0.00; Test for overall effect: Z = 3.			(P = 0.5	0); I² = I	1%			
1.3.2 recipient demise								
Eixarch 2013- recipient	9	11	96	118	11.5%	1.03 [0.21, 5.11]	2013	
Eschbach 2016: recipient Subtotal (95% CI)	19	21 32	102	121 239	12.4% 23.9%		2016	•
Total events	28		198					
Heterogeneity: Tau² = 0.00; Test for overall effect: Z = 0.			(P = 0.6	3); l² = I	0%			
Total (95% CI)		166		719	100.0%	2.28 [1.32, 3.92]		•
Total events Heterogeneity: Tau*= 0.00; Test for overall effect: Z = 2. Test for subgroup difference	.97 (P = 0.0	003)						0.01 0.1 1 10 100 Favors stage Favor stage II

Fig 4. GA at FLS in fetal demise vs alive fetus



252 Intention to receive COVID-19 vaccine during pregnancy: A systematic review and meta-analysis



Ahmed A. Nassr¹, Kamran Hessami², Stephanie Morain¹, Yalda Afshar³, Sara Arian¹, Nazlisadat Mesh¹,

Kjersti M. Aagaard⁴, Alireza A. Shamshirsaz⁵

¹Baylor College of Medicine, Houston, TX, ²Department of Obstetrics & Gynecology, Baylor College of Medicine, Houston, TX, ³University of California, Los Angeles, Los Angeles, CA, ⁴Texas Children's and Baylor College of Medicine, Houston, TX, ⁵Baylor College of Medicine/Texas Children's Hospital, Houston, TX

OBJECTIVE: To assess level of intent to receive COVID-19 vaccination and demographical factors influencing vaccine uptake among pregnant individuals.

STUDY DESIGN: Data sources: PubMed, Scopus and archive/pre-print servers were searched up to May, 2021.

Study eligibility criteria: Cross sectional surveys reporting percentage of the pregnant individuals intending to get COVID-19 vaccine were considered eligible.

Study appraisal and synthesis methods: The primary outcome was to estimate prevalence of COVID-19 vaccination intent among pregnant population. The secondary outcome was to evaluate the association of vaccine uptake with the following factors: maternal age, gravidity, marital status, medical disease, history of COVID-19 infection and if received other vaccines during pregnancy. Metaanalysis and meta-regression were used to pool estimates and examine the influencing factors.

RESULTS: Twelve studies sourcing data of 16,926 individuals who identified as pregnant were eligible. The estimated intention for receipt of COVID-19 vaccine among women who were pregnant was 47% (95% CI:38%-57%), with the lowest prevalence in Africa 19% (95% CI:17%-21%) and the highest in Oceania 48.0% (95% CI:44.0%-51.0%) (fig. 1). Association of vaccine uptake with various demographic and clinical factors is shown (fig. 2) with uptake of Poster Session I ajog.org


other vaccines during pregnancy associated with higher rate of intent to receive the COVID-19 vaccine (OR=3.03; 95% CI:1.37-6.73; P 0.006).

CONCLUSION: The intent to receive COVID-19 vaccine is relatively low among women who are pregnant and substantially varies based on country of residence. In our meta-analysis, intent of women who were pregnant to receive the COVID-19 vaccine was significantly associated history of receiving of other vaccines during pregnancy. Given that in every country only a minority of gravidae have received the COVID-19 vaccine, despite known risks of maternal morbidity and mortality with no evidence of risks of vaccination, highlights the importance of revised approaches at shared decision making and focused public health messaging by national and international advisories.

Figure 1. Included studies characteristics and global intention for COVID-19 among pregnant population

	_			_	
First author (country)	Population	Study period	Vaccination intention rate	NOS	
Ayhan (Turkey)	300	1 January to 1 February , 2021	(n=111, 37%)	7	
Battarbee (USA)	915	9 August to 10 December, 2020	(n=374, 41%)	8	
Ceulemans (multinational)	6661	10 April to 31 May 2020 and 16 June to 14 July 2020	(n=3943, 61.4%)	8	
Hoque (South Africa)	346	4 September to 3 October 2020	(n=219, 63.3%)	7	
Skirrow (UK)	799	3 August to 11 October 2020	(n=147, 18.4%)	8	
Skjefte (multinational)	5282	28 October to 18 November 2020	(n=2747, 52%)	9	
Carbone (Italy)	142	January 2021	(n=40, 28.2%)	7	
Mappa (Italy)	161	December 2020	(n=79, 49.1%)	7	
Levy (USA)	653	14 December 2020 to 14 January 2021	(n=381, 58.3%)	7	
Geoghegan (Ireland)	300	29th December 2020	(n=113, 37.7%)	8	
Tao (China)	1392	13 to 27 November 2020	(n=1077, 77.4%)	8	
Sutton (USA)	216	7 to 29 January 2021	(n= 86, 39.8%)	7	

Intention for COVID-19 vaccination uptake during pregnancy



253 Spontaneous preterm birth and PPROM After **Fetoscopic laser Surgery for TTTS- Systematic** review and Meta-analysis



Hiba J. Mustafa¹, Katherine Goetzinger², Ali Javinani³, Faezeh Aghajani¹, Christopher Harman¹, Alireza A. Shamshirsaz⁴, Magdalena Sanz Cortes⁴, Roopali V. Donepudi⁵, Eyal Krispin³, Ahmed A. Nassr³, Jimmy Espinoza⁴, Michael A. Belfort⁶, Ozhan M. Turan² ¹University of Maryland, Baltimore, MD, ²University of Maryland Medical

Center, Baltimore, MD, ³Baylor College of Medicine, Houston, TX, ⁴Baylor College of Medicine/Texas Children's Hospital, Houston, TX, ⁵Texas Children's Pavilion for Women, Baylor College of Medicine, Houston, TX, ⁶Texas Children's Hospital, Houston, TX

OBJECTIVE: To identify the prevalence and risk factors for spontaneous preterm birth (sPTB); in general; and preterm prelabor rupture of membranes (PPROM); in specific; following fetoscopic laser surgery (FLS) for twin-to-twin transfusion syndrome (TTTS) STUDY DESIGN: We searched PubMed, Scopus, and EMBASE systematically from inception until June, 2020. Multiple pre-operative, intra-operative, and post-operative factors were tabulated. The random-effect model was used to pool the odds ratios (OR) and the corresponding 95% confidence intervals (CIs). Heterogeneity was assessed using the I²value.

RESULTS: 24 studies including our cohort reporting 9060 TTTS pregnancies were included. The incidence of sPTB was 36% and incidence of PPROM was 27.4%. Significant factors for sPTB were pre-operative cervical length (CL) < 25 mm (OR: 1.52, 95% CI 1.2-1.92, I²0.0%), presence of anterior placenta (OR: 1.15, 95% CI 1.05-1.26, I²0.0%), performance of "Solomon" technique (OR: 1.27, 95%) CI 1.13-1.43, I²0.0%), septostomy (OR: 1.94, 95% CI 1.32-2.84, I²78.7%), and chorioamnion separation (CAS) (OR: 1.7, 95% CI 1.28-2.26, I²69.1%). Pre-operative cerclage placement, Gestational age (GA) at fetal intervention < 17 weeks, Intra-operative amnioinfusion and amnioreduction were not significantly associated with sPTB. Significant factors for PPROM were pre-operative CL < 25 mm (OR: 1.52, 95% CI 1.2-1.92, I²0.0%), presence of anterior placenta (OR: 1.15, 95% CI 1.01-1.31, I²0.0%), performance of "Solomon" technique (OR: 1.3, 95% CI 1.11-1.53, I²0.0%), septostomy (OR: 2.07, 95% CI 1.42-3.03, I²68%), and CAS (OR: 2.1, 95% 1.72-2.56, I²29.1%)

CONCLUSION: TTTS pregnancies with CL < 25 mm and anterior placentation have increased risk for both sPTB and PPrOM. Intraoperative factors including "Solomon" technique, septostomy, and chorioamnion separation increase the risk for sPTB and PPROM. Early GA at fetal intervention does not seem to increase that risk. This is the first meta-analysis study conducted to investigate risk factors of sPTB and PPROM following laser ablation for TTTS.